Search results
Results from the WOW.Com Content Network
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. [5]
Robert "Bob" Swanson (1947–1999) was an American venture capitalist who co-founded Genentech in 1976 with Herbert Boyer. Genentech is one of the leading biotechnology companies in the world. He was CEO of Genentech from 1976 to 1990, and chairman from 1990 to 1996. Swanson graduated from the Massachusetts Institute of Technology, where he was ...
Genencor International. Genencor is a biotechnology company based in Palo Alto, CA and a subsidiary of IFF. [1] Genencor is a producer of Industrial enzymes and low-priced bulk protein. The name Genencor originates with Genencor, Inc., the original joint venture between Genentech and Corning Incorporated, which was founded in 1982.
Formula. C6434H9940N1724O2047S45. Molar mass. 145 639.02 g·mol −1. Emicizumab, sold under the brand name Hemlibra, is a humanized bispecific monoclonal antibody for the treatment of haemophilia A, developed by Genentech and Chugai (a subsidiary of Hoffmann-La Roche ). [4] A Phase I clinical trial found that it was well tolerated by healthy ...
Efalizumab (brand name Raptiva, Genentech, Merck Serono) is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis. As implied by the suffix -zumab, it is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection.
Risdiplam is a survival of motor neuron 2 -directed RNA splicing modifier. [6] [5] [10] In clinical trials, the most common adverse events included fever, diarrhea, rash, ulcers of the mouth area, joint pain (arthralgia) and urinary tract infections. [6] [5] Additional adverse events observed in the infantile-onset population included upper ...
Dissent. Thomas. MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118 (2007), was a decision by the Supreme Court of the United States involving patent law. [1] It arose from a lawsuit filed by MedImmune which challenged one of the Cabilly patents issued to Genentech. One of the central issues was whether a licensee retained the right to challenge ...
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. [20] [17] [21] [22] It is specifically used for cancer that is HER2 receptor positive. [20] It may be used by itself or together with other chemotherapy medication. [20]